Table 2. Vessel Size and Lesion Length of the included studies.

No.	Published	Trial	inclusion	Stent Platform		drugs		Vessel Size (mm+SD)				Lesion Length (mm+SD)
				DP	BMS	DP	BMS	DP		BMS		DP		BMS
1	Lemos 2012	PAINT	de novo, native, 2.5–3.5 mm;single stent ≤29 mm	SS	SS	paclitaxel	bare	3.1	0.4	3.1	0.4	NA	NA	NA	NA
				SS	SS	Sirolimus	bare	3.1	0.3	3.1	0.4	21.8	4.8	22.5	5
2	Silber 2011	EUROSTAR II	de novo, native, 2.5–3.5 mm;leision ≤24 mm	CC	SS	paclitaxel	bare	2.74	0.51	2.73	0.48	15.12	7.58	15.16	7.69
3	Grube 2005	STEALTH	de novo, native, 2.75–4.0 mm	SS	SS	biolimus	bare	2.95	0.4	2.97	0.42	15.37	4.64	13.75	3.77
4	Räber 2012	COMFOR-AMI	STIMI	SS	SS	biolimus	bare	3.04	0.47	3.01	0.46	18.19	9.73	17.77	9.57
5	Rodriguez 2011	EUCATAX	de novo, 70% ≤stenosis	SS	SS	Paclitaxel	bare	2.75	0.5	2.85	0.5	16.2	6.1	15.6	6.3
6	Reifart 2010	CORACTO	native, CTO, 2.5–4.5 mm	SS	SS	sirolimus	bare	2.7	0.51	2.8	0.63	39.4	23.1	35.8	20.7
7	Grube 2004	FUTURE 1	de novo, 2.75–4.0 mm;leision ≤18 mm	SS	SS	Everolimus	bare	3.1	0.47	2.96	0.43	NA	NA	NA	NA